产品
编 号：F743340
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1228763-95-8
产品详情
生物活性：
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
体内研究：
Monalizumab (50 μg，瘤内注射，与 800 万个活化的 NK 细胞一起) 可有效抑制免疫缺陷小鼠异种移植 HLA-E+ 肿瘤的肿瘤生长。Animal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell
Dosage:50?μg, together with 8?millions of activated NK cells
Administration:intratumoral injections
Result:Shows a synergestic antitumor effect.Enhanced NK-cell killing, and induces lysis of tumor cells.
体外研究：
Monalizumab 阻断 NKG2A 并增强 CLL NK 细胞介导的针对表达 HLA-E 的 K562 细胞的细胞毒性。Monalizumab 增强 Enzalutamide (HY-70002) (10 μM) 诱导的 NK 细胞活化和杀伤前列腺癌细胞 (LNCaP 和 22Rv1)。
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
体内研究：
Monalizumab (50 μg，瘤内注射，与 800 万个活化的 NK 细胞一起) 可有效抑制免疫缺陷小鼠异种移植 HLA-E+ 肿瘤的肿瘤生长。Animal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell
Dosage:50?μg, together with 8?millions of activated NK cells
Administration:intratumoral injections
Result:Shows a synergestic antitumor effect.Enhanced NK-cell killing, and induces lysis of tumor cells.
体外研究：
Monalizumab 阻断 NKG2A 并增强 CLL NK 细胞介导的针对表达 HLA-E 的 K562 细胞的细胞毒性。Monalizumab 增强 Enzalutamide (HY-70002) (10 μM) 诱导的 NK 细胞活化和杀伤前列腺癌细胞 (LNCaP 和 22Rv1)。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备